Rezolute, Inc. (RZLT) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Redwood City, CA, アメリカ. 現CEOは Nevan Charles Elam.
RZLT を有する IPO日 2013-01-14, 64 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $340.78M.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
